How C. difficile Infections Work and Why They Recur

A Dangerous Opportunist Hiding in Plain Sight

Every year, Clostridioides difficile — better known as C. diff — infects roughly 500,000 people in the United States alone and kills around 30,000. It is the most common healthcare-associated infection in the developed world, yet most people have never heard of it until they or a loved one becomes a patient. Understanding how this bacterium works helps explain why it is so difficult to defeat — and why it so often comes back.

What Is C. difficile?

C. difficile is a spore-forming, gram-positive anaerobic bacterium — meaning it thrives in low-oxygen environments like the large intestine. Its most dangerous feature is its ability to produce hardy spores that can survive on dry surfaces for up to five months, resist alcohol-based hand sanitizers, and withstand most common disinfectants. This makes hospitals and long-term care facilities especially vulnerable environments for its spread.

The bacterium is widespread in nature, present in soil, water, animal intestines, and the gut of roughly 3–5% of healthy adults without causing any harm. In a healthy gut, a diverse community of beneficial bacteria keeps C. difficile in check — a principle called colonization resistance. The trouble begins when that protective community collapses.

How Infection Develops: Three Key Phases

C. diff infection (CDI) follows three well-documented stages:

1. Spore transmission: A person ingests C. diff spores, usually through contaminated surfaces, medical equipment, or unwashed hands in a healthcare setting.
2. Microbiome disruption: Antibiotics taken for an unrelated infection kill off beneficial gut bacteria. Without those competitors, C. diff spores germinate into active, toxin-producing cells.
3. Colonization and toxin production: The bacteria multiply and release two powerful toxins — Toxin A (TcdA) and Toxin B (TcdB) — that destroy the intestinal lining, trigger inflammation, and cause severe, watery diarrhea. In extreme cases, the damage leads to a life-threatening condition called toxic megacolon.

Almost any antibiotic can trigger this chain reaction, but broad-spectrum drugs such as fluoroquinolones, clindamycin, and cephalosporins carry the highest risk. Proton pump inhibitors (heartburn drugs) and advanced age are also recognized risk factors.

Why C. diff Keeps Coming Back

One of CDI's most frustrating features is its tendency to recur. Up to 35% of patients relapse after initial treatment, and each recurrence raises the odds of another. The reason lies in biology: antibiotics used to treat CDI further damage the gut microbiome, making it even harder for beneficial bacteria to recolonize and rebuild colonization resistance. Meanwhile, spores hide in the gut lining, impervious to the antibiotics that cleared the active infection, waiting for conditions to improve.

Recurrence risk climbs significantly in patients over 65, those with weakened immune systems, and anyone who has already had multiple CDI episodes.

Treatment: Old Tools and New Frontiers

Standard treatment uses targeted antibiotics — primarily fidaxomicin or vancomycin — that suppress C. diff while limiting broader microbiome damage. Fidaxomicin, the newer of the two, reduces recurrence by roughly 40% compared with vancomycin by preserving more of the beneficial gut flora.

For recurrent or severe cases, fecal microbiota transplantation (FMT) has become a recognized standard of care. FMT introduces stool from a healthy screened donor into the patient's gut, rapidly restoring a diverse bacterial community that outcompetes C. diff. Success rates range from 80% to 95%, and the US Food and Drug Administration has approved two FMT-based products specifically for recurrent CDI.

A newer direction targets the bacteria's spores directly. Researchers recently reported that an experimental compound called EVG7 can clear C. diff infection at very low doses while largely sparing the beneficial bacteria that form the gut's natural defense — potentially breaking the cycle of recurrence that current antibiotics perpetuate.

Prevention: Soap, Not Sanitizer

Because C. diff spores resist alcohol-based hand rubs, standard hospital hand sanitizers offer little protection against transmission. Soap and water physically remove spores from skin and remain the most effective prevention tool. Hospitals also use bleach-based disinfectants on surfaces, isolate infected patients, and practice antibiotic stewardship — prescribing antibiotics only when truly necessary — to reduce the conditions in which C. diff thrives.

A Reminder That the Microbiome Is Not Optional

C. diff is, in many ways, a cautionary tale about the consequences of disrupting the gut microbiome. The infection rarely happens to people with healthy, intact gut flora — it exploits the void left behind by modern medicine's most powerful tools. Research into FMT, targeted antibiotics, and microbiome-sparing drugs all point in the same direction: protecting the gut's ecosystem is not a luxury, but a medical necessity.